Piper Sandler Maintains Overweight on AbbVie, Lowers Price Target to $294

Benzinga Newsdesk www.benzinga.com Negative 76.8%

Neg 76.8% Neu 0% Pos 0%

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $299 to $294.